
  
    
      
        Synopsis_NNP
        
          Introduction_NNP
          Germline_NNP mutations_NNS in_IN the_DT breast_NN and_CC ovarian_NN cancer_NN
          susceptibility_NN gene_NN 
          BRCA_NNP 1_CD ,_, which_WDT is_VBZ located_VBN on_IN
          chromosome_NN 17_CD q_NN 21_CD ,_, are_VBP associated_VBN with_IN a_DT predisposition_NN to_TO
          the_DT development_NN of_IN cancer_NN in_IN these_DT organs_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. No_DT
          mutations_NNS in_IN the_DT 
          BRCA_NNP 1_CD gene_NN have_VBP been_VBN detected_VBN in_IN
          sporadic_JJ breast_NN cancer_NN cases_NNS ,_, but_CC mutations_NNS have_VBP been_VBN
          detected_VBN in_IN sporadic_JJ cases_NNS of_IN ovarian_NN cancer_NN [_NN 3_CD ,_, 4_CD ]_NN ._.
          Although_IN there_EX is_VBZ debate_NN regarding_VBG the_DT level_NN of_IN cancer_NN
          risk_NN associated_VBN with_IN mutations_NNS in_IN 
          BRCA_NNP 1_CD and_CC the_DT significance_NN of_IN the_DT
          lack_NN of_IN mutations_NNS in_IN sporadic_JJ tumors_NNS ,_, it_PRP is_VBZ possible_JJ that_IN
          alterations_NNS in_IN the_DT function_NN of_IN BRCA_NNP 1_CD may_MD occur_VB by_IN
          mechanisms_NNS other_JJ than_IN mutation_NN ,_, leading_VBG to_TO an_DT
          underestimation_NN of_IN risk_NN when_WRB it_PRP is_VBZ calculated_VBN solely_RB on_IN
          the_DT basis_NN of_IN mutational_NN analysis_NN ._. Such_JJ alterations_NNS cannot_NN
          be_VB identified_VBN until_IN the_DT function_NN and_CC regulation_NN of_IN BRCA_NNP 1_CD
          are_VBP better_RBR understood_VBN ._.
          The_DT 
          BRCA_NNP 1_CD gene_NN encodes_NNS a_DT 220_CD -_: kDa_NN
          nuclear_JJ phosphoprotein_NN that_WDT is_VBZ regulated_VBN in_IN response_NN to_TO
          DNA_NNP damaging_JJ agents_NNS [_NN 5_CD ,_, 6_CD ,_, 7_CD ]_NN and_CC in_IN response_NN to_TO
          estrogen-induced_JJ growth_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ._. Germline_NNP
          mutations_NNS that_WDT cause_VBP breast_NN and_CC ovarian_NN cancer_NN
          predisposition_NN frequently_RB result_NN in_IN truncated_JJ and_CC
          presumably_RB inactive_JJ BRCA_NNP 1_CD protein_NN [_NN 12_CD ]_NN ._.
          BG-_NNP 1_CD cells_NNS were_VBD derived_VBN from_IN a_DT patient_NN with_IN stage_NN III_NNP ,_,
          poorly_RB differentiated_JJ ovarian_NN adenocarcinoma_NN [_NN 13_CD ]_NN ._. This_DT
          cell_NN line_NN ,_, which_WDT expresses_VBZ wild-type_JJ BRCA_NNP 1_CD ,_, is_VBZ estrogen_NN
          responsive_JJ and_CC withdrawal_NN of_IN estrogen_NN results_NNS in_IN eventual_JJ
          cell_NN death_NN ._. Previous_JJ studies_NNS suggest_VBP that_IN BRCA_NNP 1_CD is_VBZ
          stimulated_VBN as_IN a_DT result_NN of_IN estrogen_NN treatment_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_,
          11_CD ]_NN ,_, and_CC also_RB that_IN BRCA_NNP 1_CD may_MD be_VB involved_VBN in_IN the_DT cell_NN
          death_NN process_NN [_NN 14_CD ]_NN ._. Therefore_RB ,_, we_PRP examined_VBD the_DT effect_NN of_IN
          reduction_NN of_IN BRCA_NNP 1_CD levels_NNS in_IN BG-_NNP 1_CD cells_NNS on_IN the_DT cellular_JJ
          response_NN to_TO hormone_NN depletion_NN as_RB well_RB as_IN estrogen_NN
          stimulation_NN ._. The_DT results_NNS suggest_VBP that_WDT reduced_VBD levels_NNS of_IN
          BRCA_NNP 1_CD correlates_NNS with_IN a_DT survival_NN advantage_NN when_WRB BG-_NNP 1_CD
          cells_NNS are_VBP placed_VBN under_IN growth-restrictive_JJ and_CC
          hormone-depleted_JJ conditions_NNS ._. In_IN optimum_JJ growth_NN
          conditions_NNS ,_, significantly_RB reduced_VBN levels_NNS of_IN BRCA_NNP 1_CD
          correlates_NNS with_IN enhanced_JJ growth_NN both_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN ._.
        
        
          Aims_VBZ
          To_TO test_VB the_DT hypothesis_NNS that_IN BRCA_NNP 1_CD may_MD play_VB a_DT role_NN in_IN
          the_DT regulation_NN of_IN ovarian_NN tumor_NN cell_NN death_NN as_RB well_RB as_IN in_IN
          the_DT inhibition_NN of_IN ovarian_NN cell_NN proliferation_NN ._.
        
        
          Materials_NNS and_CC methods_NNS
          The_DT estrogen_NN receptor-positive_JJ ,_, BG-_NNP 1_CD cell_NN line_NN [_NN 13_CD ]_NN ,_,
          which_WDT contains_VBZ an_DT abundant_JJ amount_NN of_IN estrogen_NN receptors_NNS
          (_( 600_CD fmoles_NNS /_NN 100_CD μg_NN DNA_NNP )_) ,_, was_VBD infected_JJ using_VBG a_DT pLXSN_NN
          retroviral_NN vector_NN (_( provided_VBN by_IN AD_NNP Miller_NNP )_) containing_VBG an_DT
          inverted_JJ partial_JJ human_JJ cDNA_NN 900_CD -_: base-pair_JJ sequence_NN of_IN
          BRCA_NNP 1_CD (_( from_IN nucleotide_NN 121_CD in_IN exon_NN 1_CD to_TO nucleotide_NN 1025_CD
          in_IN exon_NN 11_CD ,_, accession_NN #_# U_NNP 14680_CD )_) ._. After_IN 2_CD weeks_NNS of_IN
          selection_NN in_IN 800_CD μg_NN /_NN ml_NN of_IN geneticin-_NN G_NNP 418_CD (_( Gibco_NNP /_NN Life_NNP
          Technologies_NNPS ,_, Gaithersburg_NNP ,_, MD_NNP ,_, USA_NNP )_) ,_, BG-_NNP 1_CD G_NNP 418_CD -_: resistant_JJ
          colonies_NNS were_VBD pooled_VBN ,_, or_CC individually_RB isolated_VBN ,_, and_CC
          assayed_JJ for_IN growth_NN in_IN the_DT presence_NN or_CC absence_NN of_IN
          supplemented_JJ estrogen_NN ._. Virally_NNP infected_JJ pooled_VBN
          populations_NNS of_IN BG-_NNP 1_CD cells_NNS were_VBD examined_VBN for_IN BRCA_NNP 1_CD message_NN
          levels_NNS by_IN ribonuclease_NN protection_NN assay_NN (_( Fig_NNP ._. 1_LS a_DT )_) ._. BRCA_NNP 1_CD
          ribonuclease_NN protection_NN probe_NN was_VBD made_VBN using_VBG an_DT 
          in_IN vitro_NN transcription_NN kit_NN (_( Ambion_NNP ,_,
          Inc_NNP ,_, Austin_NNP ,_, TX_NNP ,_, USA_NNP )_) as_RB previously_RB described_VBD [_NN 10_CD ]_NN and_CC
          derived_VBN clones_NNS were_VBD tested_VBN for_IN protein_NN levels_NNS by_IN Western_JJ
          blot_NN analysis_NN using_VBG an_DT anti-_NN BRCA_NNP 1_CD (_( Oncogene_NNP Research_NNP ,_,
          Ab-_NNP 1_CD ,_, Cambridge_NNP ,_, MA_NNP ,_, USA_NNP )_) antibody_NN ._. Growth_NN curve_NN analysis_NN
          of_IN Infected_NNP populations_NNS and_CC were_VBD pretreated_JJ for_IN 5_CD days_NNS in_IN
          phenol_NN red-free_JJ ,_, Dulbecco_NNP 's_POS modified_VBN eagle_NN medium_NN
          (_( DMEM_NNP )_) /_NN F-_NNP 12_CD medium_NN (_( Gibco_NNP /_NN Life_NNP Technologies_NNPS )_) supplemented_JJ
          with_IN 10_CD %_NN charcoal_NN /_NN dextran_NN treated_VBD serum_NN (_( Hyclone_NNP ,_, Logan_NNP ,_,
          UT_NNP ,_, USA_NNP )_) ,_, then_RB plated_JJ at_IN 2_CD ._. 5_CD ×_NN 10_CD 6_CD cells_NNS per_IN 100_CD mm_NN dish_NN
          in_IN triplicate_NN in_IN the_DT absence_NN or_CC presence_NN of_IN estrogen_NN (_( 10_CD
          -_: 8_CD mol_NN /_NN l_NN ;_: 17_CD β-_NN Estradiol_NNP ;_: 1_CD ,_, 3_CD ,_, 5_CD (_( 10_CD )_) -_: Estratriene_NNP
          3_CD ,_, 17_CD β-diol_JJ ;_: Sigma_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ,_, USA_NNP )_) ._. For_IN soft_JJ agar_NN
          assay_NN ,_, clones_NNS were_VBD plated_JJ into_IN 10_CD 60_CD -_: mm_NN dishes_NNS at_IN 1_CD ×_NN 10_CD
          5_CD cells_NNS /_NN dish_NN containing_VBG 0_CD ._. 3_CD %_NN bactopeptone_NN agar_NN with_IN or_CC
          without_IN added_JJ estrogen_NN (_( 10_CD -_: 8_CD mol_NN /_NN l_NN )_) in_IN phenol_NN red-free_JJ
          medium_NN with_IN 10_CD %_NN stripped_VBD serum_NN in_IN order_NN to_TO test_VB for_IN
          anchorage_NN independent_JJ growth_NN ._. BG-_NNP 1_CD infected_JJ clones_NNS were_VBD
          tested_VBN for_IN tumorigenicity_NN by_IN injection_NN of_IN cells_NNS (_( 10_CD
          6_CD cells_NNS in_IN 0_CD ._. 1_CD cm_NN 250_CD %_NN matrigel_NN ;_: Collaborative_NNP Biomedical_NNP
          Products_NNPS ,_, Bedford_NNP ,_, MA_NNP ,_, USA_NNP )_) into_IN subcutaneous_JJ sites_NNS in_IN
          6_CD -_: week-old_JJ athymic_JJ Ncr-nude_NNP mice_NNS (_( NCI_NNP Animal_NNP Program_NNP ,_,
          Bethesda_NNP ,_, MD_NNP ,_, USA_NNP )_) that_WDT were_VBD ovariectomized_JJ at_IN
          approximately_RB 4_CD weeks_NNS of_IN age_NN ._. Half_NN of_IN the_DT ovariectomized_JJ
          mice_NNS received_VBD an_DT implanted_VBN 0_CD ._. 18_CD mg_NN estrogen_NN 60_CD -_: day_NN pellet_NN
          (_( Innovative_JJ Research_NNP of_IN America_NNP ,_, Sarasota_NNP ,_, FL_NNP ,_, USA_NNP )_) ._.
        
        
          Results_NNS
          Antisense_NNP technology_NN was_VBD effective_JJ in_IN decreasing_VBG both_DT
          RNA_NNP and_CC protein_NN levels_NNS of_IN BRCA_NNP 1_CD in_IN the_DT BG-_NNP 1_CD human_JJ ovarian_NN
          adenocarcinoma_NN cells_NNS ._. BRCA_NNP 1_CD antisense-infected_JJ
          populations_NNS contained_VBD significantly_RB less_JJR BRCA_NNP 1_CD message_NN
          than_IN control_NN LXSN-infected_NNP pools_NNS and_CC selected_VBN clones_NNS
          contained_VBD varying_VBG reduced_VBN levels_NNS of_IN BRCA_NNP 1_CD protein_NN
          compared_VBN with_IN control_NN clones_NNS (_( Figs_NNP 1_CD aand_NN 1_CD b_SYM )_) ._.
          Three_CD independent_JJ BRCA_NNP 1_CD antisense-infected_JJ cultures_NNS
          demonstrated_VBD a_DT resistance_NN to_TO cell_NN death_NN induced_VBN by_IN
          withdrawal_NN from_IN estrogen_NN over_IN a_DT 6_CD -_: to_TO 20_CD -_: day_NN period_NN (_( Fig_NNP ._.
          2_LS a_DT )_) ._. The_DT BRCA_NNP 1_CD antisense_NN population_NN also_RB exhibited_VBN a_DT
          threefold_RB to_TO sixfold_RB increase_VB in_IN cell_NN growth_NN compared_VBN
          with_IN control_NN cells_NNS in_IN the_DT presence_NN of_IN estrogen_NN treatment_NN ._.
          BG-_NNP 1_CD BRCA_NNP 1_CD antisense_NN clones_NNS demonstrated_VBD a_DT similar_JJ
          response_NN to_TO pooled_VBN population_NN studies_NNS ,_, enhanced_JJ growth_NN
          with_IN estrogen_NN ,_, and_CC failure_NN to_TO die_VB upon_IN estrogen_NN depletion_NN
          (_( Fig_NNP ._. 2_LS b_SYM )_) ._.
          The_DT BRCA_NNP 1_CD antisense_NN clones_NNS were_VBD further_RBR examined_VBD for_IN
          other_JJ associated_VBN tumorigenic_JJ properties_NNS ._. All_DT of_IN the_DT
          antisense_NN clones_NNS were_VBD able_JJ to_TO form_VB colonies_NNS in_IN soft_JJ agar_NN
          (_( 2_CD -_: 23_CD colonies_NNS per_IN 10_CD 4_CD cells_NNS plated_JJ ;_: data_NNS not_RB shown_VBN )_) ,_,
          whereas_IN control_NN clones_NNS were_VBD deficient_NN in_IN their_PRP$ ability_NN to_TO
          form_VB colonies_NNS (_( 0_CD -_: 0_CD ._. 8_CD colonies_NNS per_IN 10_CD 4_CD cells_NNS plated_JJ )_) ._.
          Table_NNP 1_CD shows_NNS ,_, in_IN the_DT presence_NN of_IN estrogen_NN ,_, the_DT clone_NN with_IN
          the_DT lowest_JJS levels_NNS of_IN BRCA_NNP 1_CD (_( AS-_NNP 4_LS )_) produced_VBN significantly_RB
          more_JJR colonies_NNS (_( 133_CD ±_NN 17_CD ._. 9_CD colonies_NNS per_IN 10_CD 4_CD cells_NNS plated_JJ )_)
          than_IN the_DT control_NN clone_NN (_( NEO_NNP ;_: 6_CD ±_NN 3_CD ._. 1_CD colonies_NNS per_IN 10_CD
          4_CD cells_NNS plated_JJ )_) ._. Clones_NNP AS-_NNP 4_CD and_CC NEO_NNP were_VBD also_RB injected_VBN
          with_IN matrigel_NN subcutaneously_RB into_IN ovariectomized_JJ athymic_JJ
          mice_NNS ._. Almost_RB twice_RB as_IN many_JJ sites_NNS were_VBD positive_JJ for_IN the_DT
          AS-_NNP 4_CD clone_NN (_( 14_CD out_IN of_IN 14_CD )_) as_IN for_IN the_DT NEO_NNP clone_NN (_( eight_CD out_IN
          of_IN 14_CD )_) 42_CD days_NNS after_IN injection_NN ._. In_IN addition_NN ,_, BRCA_NNP 1_CD
          antisense_NN tumors_NNS averaged_VBD twice_RB the_DT size_NN of_IN control_NN
          tumors_NNS ._. The_DT BRCA_NNP 1_CD reduced_VBN cells_NNS also_RB formed_VBN tumors_NNS with_IN
          half_PDT the_DT latency_NN of_IN control_NN cells_NNS in_IN the_DT presence_NN of_IN
          implanted_VBN estrogen_NN (_( 11_CD days_NNS versus_CC 21_CD days_NNS until_IN tumor_NN
          formation_NN )_) ._.
        
        
          Discussion_NNP
          The_DT present_JJ studies_NNS show_VBP that_DT reduction_NN in_IN BRCA_NNP 1_CD
          levels_NNS ,_, using_VBG an_DT antisense_NN retroviral_NN vector_NN in_IN the_DT
          estrogen_NN dependent_JJ BG-_NNP 1_CD ovarian_NN carcinoma_NN cell_NN line_NN ,_,
          contributes_VBZ to_TO confirmation_NN of_IN the_DT hypothesis_NNS that_IN 
          BRCA_NNP 1_CD plays_VBZ a_DT pivotal_JJ role_NN in_IN the_DT
          balance_NN between_IN cell_NN death_NN and_CC cell_NN proliferation_NN ._. 
          BRCA_NNP 1_CD RNA_NNP and_CC protein_NN levels_NNS were_VBD
          successfully_RB reduced_VBN in_IN populations_NNS and_CC isolated_VBN clones_NNS
          of_IN antisense_NN infected_JJ BG-_NNP 1_CD cells_NNS ._. Decreased_NNP 
          BRCA_NNP 1_CD levels_NNS rescued_VBD the_DT BG-_NNP 1_CD cells_NNS
          from_IN growth_NN arrest_NN or_CC cell_NN death_NN in_IN adverse_JJ growth_NN
          conditions_NNS in_IN monolayer_NN or_CC soft_JJ agar_NN conditions_NNS ._.
          Furthermore_RB ,_, a_DT BRCA_NNP 1_CD antisense_NN clone_NN that_WDT had_VBD
          significantly_RB low_JJ levels_NNS of_IN BRCA_NNP 1_CD protein_NN was_VBD able_JJ to_TO
          form_VB twice_RB as_IN many_JJ tumors_NNS in_IN ovariectomized_JJ nude_JJ mice_NNS
          with_IN a_DT decreased_VBN latency_NN compared_VBN with_IN a_DT control_NN
          clone_NN ._.
          In_IN multicellular_NN mammalian_JJ organisms_NNS ,_, a_DT balance_NN
          between_IN cell_NN proliferation_NN and_CC cell_NN death_NN is_VBZ extremely_RB
          important_JJ for_IN the_DT maintenance_NN of_IN normal_JJ healthy_JJ tissues_NNS ._.
          In_IN support_NN of_IN this_DT hypothesis_NNS ,_, it_PRP has_VBZ been_VBN shown_VBN that_DT 
          p_NN 53_CD and_CC 
          BRCA_NNP 1_CD can_MD form_VB stable_JJ complexes_NNS ,_,
          and_CC can_MD coactivate_NN 
          p_NN 21_CD and_CC 
          bax_NN genes_NNS ,_, which_WDT may_MD lead_VB to_TO the_DT
          activation_NN of_IN the_DT apoptosis_NNS pathway_NN [_NN 15_CD ]_NN ._. The_DT present_JJ
          data_NN ,_, which_WDT show_VBP that_IN cells_NNS with_IN a_DT reduction_NN of_IN BRCA_NNP 1_CD
          have_VBP a_DT survival_NN advantage_NN in_IN conditions_NNS where_WRB control_NN
          cells_NNS fail_VBP to_TO thrive_VB ,_, also_RB supports_VBZ this_DT hypothesis_NNS ._. 
          BRCA_NNP 1_CD levels_NNS appear_VBP to_TO affect_VB the_DT
          ability_NN of_IN cells_NNS to_TO arrest_VB growth_NN or_CC die_VB in_IN the_DT absence_NN
          of_IN estrogenic_JJ growth-inducing_JJ conditions_NNS ._. Although_IN
          mutations_NNS in_IN this_DT gene_NN are_VBP uncommon_JJ in_IN sporadic_JJ breast_NN
          and_CC ovarian_NN tumors_NNS ,_, 
          BRCA_NNP 1_CD expression_NN levels_NNS and_CC protein_NN
          levels_NNS have_VBP been_VBN found_VBN to_TO be_VB reduced_VBN in_IN sporadic_JJ human_JJ
          breast_NN carcinomas_NNS [_NN 16_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ]_NN ._. In_IN addition_NN it_PRP has_VBZ
          been_VBN demonstrated_VBN [_NN 20_CD ]_NN that_IN hormone-dependent_JJ tumors_NNS
          such_JJ as_IN breast_NN and_CC ovarian_NN cancers_NNS have_VBP a_DT decreased_VBN
          ability_NN to_TO undergo_VB apoptosis_NNS ._. Other_JJ mechanisms_NNS involving_VBG
          gene_NN regulation_NN may_MD allow_VB for_IN decreased_VBD expression_NN of_IN 
          BRCA_NNP 1_CD in_IN sporadic_JJ tumors_NNS ._. The_DT
          response_NN of_IN 
          BRCA_NNP 1_CD mRNA_NN and_CC protein_NN levels_NNS to_TO
          mitogens_NNS and_CC hormones_NNS 
          in_IN vitro_NN suggests_VBZ that_IN 
          BRCA_NNP 1_CD may_MD play_VB a_DT role_NN in_IN regulation_NN
          of_IN cell_NN growth_NN or_CC maintenance_NN [_NN 21_CD ]_NN ._. The_DT BRCA_NNP 1_CD gene_NN
          product_NN may_MD be_VB involved_VBN in_IN the_DT regulation_NN of_IN hormone_NN
          response_NN pathways_NNS ,_, and_CC the_DT present_JJ results_NNS demonstrate_VBP
          that_DT loss_NN of_IN BRCA_NNP 1_CD may_MD result_VB in_IN loss_NN of_IN inhibitory_NN
          control_NN of_IN these_DT mitogenic_JJ pathways_NNS ._. These_DT studies_NNS show_VBP
          that_DT reduction_NN in_IN 
          BRCA_NNP 1_CD mRNA_NN and_CC protein_NN can_MD result_VB
          in_IN increased_VBN proliferation_NN of_IN BG-_NNP 1_CD ovarian_NN cancer_NN cells_NNS
          in_IN both_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN conditions_NNS ,_, suggesting_VBG that_DT
          
          BRCA_NNP 1_CD may_MD normally_RB be_VB acting_VBG as_IN a_DT
          growth_NN inhibitor_NN ._. Low_NNP BRCA_NNP 1_CD levels_NNS found_VBD in_IN sporadic_JJ
          cancers_NNS may_MD be_VB an_DT important_JJ factor_NN in_IN tumorigenesis_NNS ._. The_DT
          present_JJ data_NN suggest_VBP that_WDT diminished_VBD levels_NNS of_IN 
          BRCA_NNP 1_CD not_RB only_RB accelerate_VB
          proliferation_NN in_IN the_DT BG-_NNP 1_CD ovarian_NN carcinoma_NN cell_NN line_NN ,_,
          but_CC also_RB appear_VB to_TO promote_VB tumorigenesis_NNS ._. We_PRP propose_VBP that_IN
          the_DT loss_NN or_CC reduction_NN of_IN 
          BRCA_NNP 1_CD may_MD predispose_VB a_DT cell_NN
          population_NN to_TO neoplastic_JJ transformation_NN by_IN altering_VBG the_DT
          balance_NN between_IN cell_NN death_NN and_CC proliferation_NN /_NN survival_NN ,_,
          rendering_VBG it_PRP more_RBR sensitive_JJ to_TO secondary_JJ genetic_JJ
          changes_NNS ._.
        
      
      
        Introduction_NNP
        Germline_NNP mutations_NNS in_IN the_DT breast_NN and_CC ovarian_NN cancer_NN
        susceptibility_NN gene_NN 
        BRCA_NNP 1_CD ,_, which_WDT is_VBZ located_VBN on_IN
        chromosome_NN 17_CD q_NN 21_CD ,_, are_VBP associated_VBN with_IN a_DT predisposition_NN to_TO
        the_DT development_NN of_IN cancer_NN in_IN these_DT organs_NNS [_NN 1_CD ,_, 2_CD ]_NN ._. Initial_JJ
        analyses_NNS [_NN 22_CD ]_NN suggested_VBD that_IN women_NNS with_IN germline_NN mutations_NNS
        in_IN the_DT 
        BRCA_NNP 1_CD gene_NN and_CC a_DT strong_JJ family_NN
        history_NN of_IN breast_NN or_CC ovarian_NN cancer_NN have_VBP 85_CD and_CC 44_CD %_NN
        lifetime_NN risks_NNS of_IN developing_VBG breast_NN and_CC ovarian_NN cancer_NN ,_,
        respectively_RB ._. Recent_JJ studies_NNS [_NN 23_CD ]_NN ,_, however_RB ,_, have_VBP suggested_VBN
        that_IN analyses_NNS based_VBN on_IN women_NNS who_WP were_VBD not_RB selected_VBN for_IN a_DT
        familial_NN history_NN of_IN cancer_NN indicate_VBP that_IN the_DT risk_NN for_IN
        cancer_NN associated_VBN with_IN mutations_NNS in_IN these_DT genes_NNS is_VBZ 50_CD and_CC
        16_CD %_NN for_IN breast_NN and_CC ovarian_NN cancers_NNS ,_, respectively_RB ._. No_DT
        mutations_NNS in_IN the_DT 
        BRCA_NNP 1_CD gene_NN have_VBP been_VBN detected_VBN in_IN
        sporadic_JJ breast_NN cancer_NN cases_NNS ;_: however_RB ,_, mutations_NNS have_VBP been_VBN
        detected_VBN in_IN sporadic_JJ cases_NNS of_IN ovarian_NN cancer_NN [_NN 3_CD ,_, 4_CD ]_NN ._.
        Although_IN there_EX is_VBZ debate_NN regarding_VBG the_DT level_NN of_IN cancer_NN risk_NN
        associated_VBN with_IN mutations_NNS in_IN 
        BRCA_NNP 1_CD and_CC the_DT significance_NN of_IN the_DT
        lack_NN of_IN mutations_NNS in_IN sporadic_JJ tumors_NNS ,_, it_PRP is_VBZ possible_JJ that_IN
        alterations_NNS in_IN the_DT function_NN of_IN BRCA_NNP 1_CD may_MD occur_VB by_IN
        mechanisms_NNS other_JJ than_IN mutation_NN ._. This_DT would_MD lead_VB to_TO an_DT
        underestimation_NN of_IN risk_NN when_WRB it_PRP is_VBZ calculated_VBN solely_RB on_IN the_DT
        basis_NN of_IN mutational_NN analysis_NN ._. Such_JJ alterations_NNS cannot_NN be_VB
        identified_VBN until_IN the_DT function_NN and_CC regulation_NN of_IN BRCA_NNP 1_CD are_VBP
        better_RBR understood_VBN ._.
        The_DT 
        BRCA_NNP 1_CD gene_NN encodes_NNS a_DT 220_CD -_: kDa_NN nuclear_JJ
        protein_NN that_WDT may_MD be_VB regulated_VBN by_IN phosphorylation_NN through_IN
        the_DT cell_NN cycle_NN and_CC in_IN response_NN to_TO DNA_NNP damaging_JJ agents_NNS [_NN 5_CD ,_,
        6_CD ,_, 7_CD ]_NN ._. The_DT level_NN of_IN BRCA_NNP 1_CD is_VBZ also_RB regulated_VBN in_IN response_NN to_TO
        estrogen_NN or_CC estrogen-induced_JJ growth_NN in_IN breast_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_,
        11_CD ]_NN and_CC ovarian_NN cell_NN lines_NNS ._. BRCA_NNP 1_CD has_VBZ been_VBN shown_VBN to_TO
        colocalize_NN in_IN nuclear_JJ dots_NNS with_IN other_JJ cellular_JJ proteins_NNS ,_,
        including_VBG BARD-_NNP 1_CD [_NN 24_CD ]_NN ,_, Rad_NNP 51_CD ,_, PCNA_NNP ,_, and_CC BRCA_NNP 2_CD [_NN 7_CD ,_, 25_CD ]_NN ._. In_IN
        addition_NN ,_, BRCA_NNP 1_CD can_MD act_VB as_IN a_DT transcriptional_NN transactivator_NN
        in_IN yeast_NN reporter_NN assays_NNS [_NN 26_CD ,_, 27_CD ]_NN and_CC binds_NNS the_DT RNA_NNP
        polymerase_NN II_NNP holoenzyme_NN ,_, a_DT component_NN of_IN the_DT basal_NN
        transcription_NN machinery_NN [_NN 25_CD ]_NN ._. The_DT precise_JJ mechanism_NN of_IN
        action_NN and_CC the_DT specific_JJ signaling_VBG pathway_NN affected_VBN by_IN BRCA_NNP 1_CD
        remain_VB unknown_JJ ,_, however_RB ._.
        Studies_NNS of_IN 
        BRCA_NNP 1_CD expression_NN patterns_NNS in_IN mouse_NN
        tissue_NN reveal_VB that_IN BRCA_NNP 1_CD is_VBZ most_RBS highly_RB expressed_VBD in_IN
        tissues_NNS undergoing_VBG rapid_JJ proliferation_NN and_CC differentiation_NN ,_,
        and_CC that_DT expression_NN 
        in_IN vivo_NN is_VBZ also_RB hormone_NN responsive_JJ ._.
        For_IN example_NN ,_, analyses_NNS of_IN mammary_JJ gland_NN growth_NN and_CC
        development_NN show_NN high_JJ levels_NNS of_IN BRCA_NNP 1_CD expression_NN in_IN
        terminal_NN end_NN buds_NNS during_IN puberty_NN and_CC in_IN budding_VBG alveoli_NN
        during_IN pregnancy_NN ._. In_IN addition_NN ,_, hormonal_NN stimulation_NN in_IN
        ovariectomized_JJ mice_NNS results_NNS in_IN induction_NN of_IN BRCA_NNP 1_CD
        expression_NN in_IN the_DT breast_NN [_NN 28_CD ]_NN ._. Attempts_NNS to_TO develop_VB
        homozygous_JJ ,_, BRCA_NNP 1_CD -_: deleted_VBN mouse_NN models_NNS have_VBP resulted_VBN in_IN
        embryonic_JJ lethality_NN [_NN 29_CD ,_, 30_CD ]_NN ._. For_IN example_NN ,_, when_WRB the_DT 
        BRCA_NNP 1_CD gene_NN deletion_NN was_VBD targeted_VBN in_IN
        exons_NNS 5_CD and_CC 6_CD ,_, mutant_JJ mice_NNS died_VBD before_IN day_NN 7_CD ._. 5_CD of_IN
        embryogenesis_NNS ._. Analysis_NNP of_IN DNA_NNP synthesis_NN in_IN the_DT mutant_JJ
        embryos_NNS indicated_VBD that_DT cell_NN proliferation_NN was_VBD impaired_VBN ,_,
        suggesting_VBG that_IN BRCA_NNP 1_CD may_MD paradoxically_RB play_VB a_DT positive_JJ
        role_NN in_IN the_DT regulation_NN of_IN embryonic_JJ cell_NN growth_NN [_NN 29_CD ]_NN ._.
        Most_JJS of_IN the_DT mechanistic_JJ BRCA_NNP 1_CD studies_NNS to_TO date_NN have_VBP been_VBN
        conducted_VBN in_IN breast_NN carcinoma_NN cell_NN lines_NNS ;_: therefore_RB ,_, we_PRP
        decided_VBD to_TO conduct_VB a_DT study_NN to_TO determine_VB the_DT effect_NN of_IN BRCA_NNP 1_CD
        expression_NN on_IN the_DT cellular_JJ phenotype_NN of_IN an_DT ovarian_NN
        carcinoma_NN cell_NN line_NN ,_, BG-_NNP 1_CD ._. BG-_NNP 1_CD cells_NNS were_VBD derived_VBN from_IN a_DT
        patient_NN with_IN stage_NN III_NNP ,_, poorly_RB differentiated_JJ ovarian_NN
        adenocarcinoma_NN [_NN 13_CD ]_NN ._. This_DT cell_NN line_NN ,_, which_WDT expresses_VBZ
        wild-type_JJ BRCA_NNP 1_CD ,_, is_VBZ estrogen_NN responsive_JJ ,_, and_CC withdrawal_NN of_IN
        estrogen_NN results_NNS in_IN eventual_JJ cell_NN death_NN ._. Previous_JJ studies_NNS
        suggested_VBD that_IN BRCA_NNP 1_CD is_VBZ stimulated_VBN as_IN a_DT result_NN of_IN estrogen_NN
        treatment_NN [_NN 8_CD ,_, 9_CD ,_, 10_CD ,_, 11_CD ]_NN ,_, and_CC that_IN BRCA_NNP 1_CD may_MD be_VB involved_VBN
        in_IN the_DT cell_NN death_NN process_NN [_NN 14_CD ]_NN ._. Therefore_RB ,_, we_PRP examined_VBD the_DT
        effect_NN of_IN reduction_NN of_IN BRCA_NNP 1_CD levels_NNS in_IN BG-_NNP 1_CD cells_NNS on_IN the_DT
        cellular_JJ response_NN to_TO estrogen_NN stimulation_NN as_RB well_RB as_IN
        hormone_NN depletion_NN ._. Our_PRP$ results_NNS suggest_VBP that_IN when_WRB BG-_NNP 1_CD cells_NNS
        are_VBP subjected_VBN to_TO growth_VB restrictive_JJ and_CC hormone-depleted_JJ
        conditions_NNS ,_, cells_NNS that_WDT have_VBP even_RB moderately_RB reduced_VBN levels_NNS
        of_IN BRCA_NNP 1_CD protein_NN have_VBP a_DT distinct_JJ advantage_NN for_IN survival_NN ._. In_IN
        addition_NN ,_, significant_JJ reduction_NN in_IN BRCA_NNP 1_CD protein_NN level_NN
        correlates_NNS with_IN enhanced_JJ estrogen_NN proliferation_NN when_WRB
        compared_VBN with_IN cells_NNS that_WDT express_VBP moderate_JJ to_TO wild-type_JJ
        BRCA_NNP 1_CD levels_NNS ,_, grown_VBN under_IN optimal_NN growth_NN conditions_NNS both_DT 
        in_IN vitro_NN and_CC 
        in_IN vivo_NN ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Cells_NNP and_CC cell_NN culture_NN
          The_DT estrogen_NN receptor-positive_JJ ,_, BG-_NNP 1_CD line_NN [_NN 13_CD ]_NN ,_, which_WDT
          contains_VBZ an_DT abundant_JJ amount_NN of_IN estrogen_NN receptors_NNS (_( 600_CD
          fmol_NN /_NN 100_CD μg_NN DNA_NNP )_) ,_, was_VBD provided_VBN by_IN J_NNP Boyd_NNP (_( Sloan-_NNP Kettering_NNP
          Cancer_NNP Center_NNP ,_, New_NNP York_NNP ,_, NY_NNP ,_, USA_NNP )_) ._. GPE_NNP 86_CD and_CC PA_NNP 317_CD viral_JJ
          packaging_VBG cell_NN lines_NNS were_VBD provided_VBN by_IN AD_NNP Miller_NNP (_( Fred_NNP
          Hutchinson_NNP Cancer_NNP Center_NNP ,_, Seattle_NNP ,_, WA_NNP ,_, USA_NNP )_) ._. BG-_NNP 1_CD cells_NNS
          were_VBD maintained_VBN in_IN Dulbecco_NNP 's_POS modified_VBN eagle_NN medium_NN
          (_( DMEM_NNP )_) /_NN F_NN 12_CD medium_NN supplemented_JJ with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN
          (_( Summit_NNP ,_, Fort_NNP Collins_NNP ,_, CO_NNP ,_, USA_NNP )_) ,_, and_CC 50_CD units_NNS /_NN ml_NN
          penicillin_NN /_NN streptomycin_NN ._. BG-_NNP 1_CD cells_NNS arrest_NN to_TO gamma_NN
          radiation_NN consistent_JJ with_IN a_DT wildtype_NN 
          p_NN 53_CD phenotype_NN ._. These_DT cells_NNS were_VBD
          tested_VBN negative_JJ for_IN mycoplasmas_NNS ._.
        
        
          Retroviral_NNP vector_NN preparation_NN and_CC infection_NN of_IN
          cells_NNS
          A_DT partial_JJ human_JJ cDNA_NN sequence_NN of_IN 
          BRCA_NNP 1_CD (_( from_IN nucleotide_NN 121_CD in_IN exon_NN
          1_CD to_TO nucleotide_NN 1025_CD in_IN exon_NN 11_CD ,_, accession_NN #_# U_NNP 14680_CD )_) was_VBD
          inserted_VBN in_IN the_DT antisense_NN orientation_NN into_IN the_DT EcoR_NNP 1_CD site_NN
          of_IN the_DT pLXSN_NN retroviral_NN vector_NN (_( provided_VBN by_IN AD_NNP Miller_NNP )_) ._.
          The_DT vector_NN alone_RB ,_, or_CC the_DT antisense_NN 
          BRCA_NNP 1_CD vector_NN ,_, was_VBD transfected_JJ using_VBG
          the_DT calcium-phosphate_JJ precipitation_NN method_NN into_IN the_DT
          ecotropic_JJ packaging_NN cell_NN line_NN GPE_NNP 86_CD [_NN 31_CD ]_NN ._. Supernatant_NNP ,_,
          generated_VBN from_IN transfected_JJ GPE_NNP 86_CD cells_NNS [_NN 31_CD ]_NN ,_, was_VBD then_RB
          used_VBN to_TO infect_NN the_DT amphotropic_JJ packaging_NN cell_NN line_NN PA_NNP 317_CD
          [_NN 31_CD ]_NN in_IN the_DT presence_NN of_IN 4_CD μg_NN /_NN ml_NN polybrene_NN (_( Abbott_NNP
          Laboratories_NNPS ,_, Abbott_NNP Park_NNP ,_, IL_NNP ,_, USA_NNP )_) ._. PA_NNP 317_CD -_: infected_JJ cells_NNS
          were_VBD grown_VBN in_IN selection_NN media_NNS for_IN 2_CD weeks_NNS and_CC pooled_VBN for_IN
          supernatant_NN collection_NN ._. Supernatants_NNP were_VBD filtered_VBN (_( 0_CD ._. 20_CD
          μm_NN filter_NN )_) and_CC tested_VBN for_IN virus-producing_JJ cells_NNS ._. Titer_NNP
          efficiencies_NNS of_IN the_DT LXSN_NNP virus_NN ranged_VBD from_IN 10_CD 4_CD to_TO 10_CD
          5_CD colony-forming_JJ units_NNS /_NN ml_NN on_IN mouse_NN cells_NNS (_( A_DT 9_CD )_) ._. Log_NNP phase_NN
          BG-_NNP 1_CD cells_NNS were_VBD exposed_VBN to_TO supernatant_NN containing_VBG either_CC
          the_DT LXSN_NNP control_NN retrovirus_JJ or_CC retroviruses_NNS containing_VBG
          the_DT antisense_NN 
          BRCA_NNP 1_CD cDNA_NN sequence_NN ._. After_IN 2_CD weeks_NNS
          of_IN selection_NN in_IN 800_CD μg_NN /_NN ml_NN of_IN geneticin-_NN G_NNP 418_CD (_( Gibco_NNP /_NN Life_NNP
          Technologies_NNPS ,_, Gaithersburg_NNP ,_, MD_NNP ,_, USA_NNP )_) ,_, BG-_NNP 1_CD G_NNP 418_CD -_: resistant_JJ
          colonies_NNS were_VBD pooled_VBN or_CC individually_RB isolated_VBN and_CC assayed_JJ
          for_IN growth_NN in_IN the_DT presence_NN or_CC absence_NN of_IN supplemented_JJ
          estrogen_NN ._. Only_RB isolated_VBN clones_NNS were_VBD used_VBN in_IN anchorage_NN
          dependence_NN and_CC tumorigenicity_NN studies_NNS ._.
        
        
          BRCA_NNP 1_CD ribonuclease_NN protection_NN assay_NN and_CC protein_NN
          analysis_NN
          A_DT BRCA_NNP 1_CD ribonuclease_NN protection_NN probe_NN was_VBD made_VBN using_VBG
          an_DT 
          In_IN Vitro_NNP Transcription_NNP Kit_NNP (_( Ambion_NNP ,_,
          Inc_NNP ,_, Austin_NNP ,_, TX_NNP ,_, USA_NNP )_) ._. The_DT DNA_NNP template_NN spanned_VBD part_NN of_IN
          exon_NN 22_CD ,_, all_DT of_IN exon_NN 23_CD ,_, and_CC part_NN of_IN exon_NN 24_CD of_IN the_DT 
          BRCA_NNP 1_CD gene_NN ._. Template_NNP DNA_NNP was_VBD
          incubated_JJ for_IN 45_CD min_NN at_IN 37_CD °_NN C_NNP with_IN (_( α-_NN 32_CD P_NN )_) -_: uridine_NN
          triphosphate_NN and_CC T_NN 7_CD polymerase_NN in_IN the_DT presence_NN of_IN buffer_NN
          and_CC nucleotides_NNS ._. DNA_NN template_NN was_VBD removed_VBN by_IN
          ribonuclease-free_JJ deoxyribonuclease_NN incubation_NN at_IN 37_CD °_NN C_NNP
          for_IN 30_CD min_NN ._. The_DT reaction_NN was_VBD stopped_VBN by_IN the_DT addition_NN of_IN
          0_CD ._. 5_CD mol_NN /_NN l_NN ethylenediaminetetra-acetic_JJ acid_NN ,_, and_CC the_DT
          labeled_VBN probe_NN was_VBD purified_JJ on_IN a_DT 5_CD %_NN polyacrylamide_NN gel_NN ._.
          Sample_NNP RNA_NNP (_( 20_CD μg_NN total_JJ RNA_NNP )_) was_VBD coprecipitated_JJ with_IN the_DT
          BRCA_NNP 1_CD probe_NN and_CC the_DT cyclophilin_NN control_NN probe_NN [_NN 32_CD ]_NN ,_,
          resuspended_JJ in_IN Hyb-speed_NNP RPA_NNP (_( Ambion_NNP )_) hybridization_NN
          buffer_NN at_IN 95_CD °_NN C_NNP ,_, and_CC then_RB incubated_JJ at_IN 68_CD °_NN C_NNP for_IN 10_CD min_NN ._.
          Ribonuclease_NNP was_VBD added_VBN and_CC the_DT sample_NN was_VBD incubated_JJ for_IN
          45_CD min_NN at_IN 37_CD °_NN C_NNP ._. Protected_NNP fragments_NNS were_VBD precipitated_VBD ,_, and_CC
          resuspended_JJ in_IN loading_NN buffer_NN ,_, followed_VBN by_IN separation_NN on_IN
          a_DT 5_CD %_NN polyacrylamide-urea_JJ gel_NN ,_, and_CC exposed_VBD to_TO X-_NNP ray_NN
          film_NN ._.
          BRCA_NNP 1_CD protein_NN was_VBD analyzed_VBN by_IN Western_JJ blot_NN analysis_NN ._.
          Whole_JJ cell_NN lysate_NN (_( 50_CD μg_NN )_) was_VBD loaded_VBN onto_IN a_DT 6_CD %_NN sodium_NN
          dodecyl_NN sulfate-polyacrylamide_JJ gel_NN electrophoresis_NNS gel_NN ,_,
          transferred_VBN to_TO nitrocellulose_NN ,_, and_CC hybridized_JJ with_IN an_DT
          anti-_NN BRCA_NNP 1_CD (_( Ab-_NNP 1_CD ;_: Oncogene_NNP Research_NNP ,_, Cambridge_NNP ,_, MA_NNP ,_, USA_NNP )_)
          antibody_NN as_RB previously_RB described_VBD [_NN 10_CD ]_NN ._.
        
        
          Estrogen_NNP treatment_NN and_CC growth_NN curve_NN analysis_NN
          G_NNP 418_CD -_: resistant_JJ colonies_NNS from_IN 
          BRCA_NNP 1_CD antisense_NN infected_JJ BG-_NNP 1_CD cells_NNS
          and_CC control_NN vector_NN LXSN-infected_NNP BG-_NNP 1_CD cells_NNS were_VBD pooled_VBN ,_,
          pretreated_JJ for_IN 5_CD days_NNS in_IN phenol_NN red-free_JJ ,_, DMEM_NNP /_NN F-_NNP 12_CD
          medium_NN (_( Gibco_NNP /_NN Life_NNP Technologies_NNPS )_) supplemented_JJ with_IN 10_CD %_NN
          charcoal_NN /_NN dextran_NN treated_VBD serum_NN (_( Hyclone_NNP ,_, Logan_NNP ,_, UT_NNP ,_, USA_NNP )_) ,_,
          then_RB plated_JJ at_IN 2_CD ._. 5_CD ×_NN 10_CD 6_CD cells_NNS per_IN 100_CD mm_NN dish_NN in_IN
          triplicate_NN for_IN growth_NN curve_NN analysis_NN in_IN the_DT absence_NN or_CC
          presence_NN of_IN estrogen_NN (_( 10_CD -_: 8_CD mol_NN /_NN l_NN ;_: 17_CD β-_NN Estradiol_NNP ;_: 1_CD ,_, 3_CD ,_, 5_CD
          (_( 10_CD )_) -_: Estratriene_NNP 3_CD ,_, 17_CD β-diol_JJ ;_: Sigma_NNP ,_, St_NNP Louis_NNP ,_, MO_NNP ,_,
          USA_NNP )_) ._. Extended_NNP growth_NN curve_NN analysis_NN was_VBD plated_JJ at_IN 2_CD ._. 5_CD ×_NN
          10_CD 6_CD in_IN 100_CD mm_NN dishes_NNS for_IN an_DT extended_VBN treatment_NN of_IN 20_CD days_NNS
          without_IN estrogen_NN ._. Clones_NNP were_VBD isolated_VBN from_IN the_DT 
          BRCA_NNP 1_CD antisense_NN and_CC LXSN_NNP BG-_NNP 1_CD
          pooled_VBN populations_NNS and_CC grown_VBN in_IN phenol_NN red-free_JJ ,_,
          DMEM_NNP /_NN F-_NNP 12_CD medium_NN (_( Gibco_NNP /_NN Life_NNP Technologies_NNPS )_) supplemented_JJ
          with_IN charcoal_NN /_NN dextran_NN treated_VBD serum_NN (_( Hyclone_NNP )_) for_IN 5_CD days_NNS
          before_IN plating_VBG for_IN growth_NN curve_NN analysis_NN ._. Cells_NNP were_VBD then_RB
          plated_JJ in_IN triplicate_NN at_IN 1_CD ×_NN 10_CD 6_CD cells_NNS per_IN 60_CD mm_NN dish_NN in_IN
          either_DT the_DT absence_NN or_CC presence_NN of_IN estrogen_NN (_( 10_CD -_: 8_CD mol_NN /_NN l_NN )_)
          and_CC grown_VBN for_IN 8_CD -_: 10_CD days_NNS ._. Cell_NNP number_NN was_VBD calculated_VBN on_IN
          indicated_VBD days_NNS using_VBG a_DT Coulter_NNP counter_NN ._. The_DT number_NN of_IN
          dead_JJ cells_NNS for_IN the_DT extended_VBN growth_NN curve_NN experiment_NN was_VBD
          calculated_VBN by_IN counting_VBG trypan_NN blue_JJ incorporated_VBN cells_NNS
          using_VBG a_DT hemocytometer_NN ._. Statistical_NNP analyses_NNS of_IN 
          P_NN values_NNS were_VBD calculated_VBN based_VBN on_IN
          the_DT fold_VB differences_NNS between_IN growth_NN of_IN the_DT clones_NNS by_IN
          computing_VBG a_DT mean_JJ ratio_NN and_CC the_DT corresponding_JJ standard_JJ
          deviation_NN [_NN 33_CD ]_NN ._.
        
        
          Anchorage_NNP independence_NN analysis_NN and_CC
          tumorigenicity_NN
          Selected_JJ BG-_NNP 1_CD clones_NNS were_VBD tested_VBN for_IN anchorage_NN
          independent_JJ growth_NN in_IN 0_CD ._. 3_CD %_NN bacto-peptone_JJ agar_NN with_IN a_DT 0_CD ._. 6_CD %_NN
          bacto-peptone_JJ agar_NN base_NN plus_CC or_CC minus_CC added_VBD estrogen_NN (_( 10_CD
          -_: 8_CD mol_NN /_NN l_NN )_) in_IN phenol_NN red-free_JJ medium_NN with_IN 10_CD %_NN stripped_VBD
          serum_NN ._. Each_DT BG-_NNP 1_CD ,_, neomycin-resistant_JJ clone_NN was_VBD plated_JJ
          into_IN 10_CD 60_CD -_: mm_NN dishes_NNS containing_VBG the_DT agar_NN at_IN 1_CD ×_NN 10_CD 5_CD cells_NNS
          per_IN dish_NN ._. Colonies_NNP (_( greater_JJR than_IN 30_CD cells_NNS )_) were_VBD scored_VBN
          after_IN 14_CD days_NNS ._. Pairwise_NNP comparisons_NNS were_VBD made_VBN by_IN a_DT
          two-sided_JJ Mann-_NNP Whitney_NNP U_NNP test_NN to_TO calculate_VB 
          P_NN values_NNS [_NN 34_CD ]_NN ._.
          BG-_NNP 1_CD -_: infected_JJ clones_NNS were_VBD tested_VBN for_IN tumorigenicity_NN in_IN
          6_CD -_: week-old_JJ athymic_JJ Ncr-nude_NNP mice_NNS (_( NCI_NNP Animal_NNP Program_NNP ,_,
          Bethesda_NNP ,_, MD_NNP ,_, USA_NNP )_) that_WDT were_VBD ovariectomized_JJ at_IN
          approximately_RB 4_CD weeks_NNS of_IN age_NN ._. BRCA_NNP 1_CD antisense_NN clone_NN
          (_( AS-_NNP 4_LS )_) was_VBD injected_VBN (_( 10_CD 6_CD cells_NNS in_IN 0_CD ._. 1_CD cm_NN 250_CD %_NN matrigel_NN ;_:
          Collaborative_NNP Biomedical_NNP Products_NNPS ,_, Bedford_NNP ,_, MA_NNP ,_, USA_NNP )_) into_IN
          two_CD subcutaneous_JJ sites_NNS on_IN one_CD side_NN of_IN 16_CD mice_NNS (_( 32_CD
          injection_NN sites_NNS )_) ,_, whereas_IN a_DT LXSN_NNP control_NN clone_NN was_VBD
          injected_VBN on_IN the_DT opposite_JJ side_NN of_IN the_DT same_JJ mice_NNS ._. Nine_CD of_IN
          the_DT 16_CD ovariectomized_JJ mice_NNS also_RB received_VBD an_DT implanted_VBN
          0_CD ._. 18_CD mg_NN estrogen_NN 60_CD -_: day_NN pellet_NN (_( Innovative_JJ Research_NNP of_IN
          America_NNP ,_, Sarasota_NNP ,_, FL_NNP ,_, USA_NNP )_) ._. Mice_NNS were_VBD periodically_RB
          examined_VBN and_CC tumor_NN size_NN was_VBD measured_VBN during_IN the_DT 3_CD -_: month_NN
          period_NN after_IN injection_NN ._.
        
      
      
        Results_NNS
        
          Effective_NNP decrease_VB in_IN BRCA_NNP 1_CD expression_NN using_VBG
          antisense_NN technology_NN
          Antisense_NNP technology_NN was_VBD effective_JJ in_IN decreasing_VBG both_DT
          RNA_NNP and_CC protein_NN levels_NNS of_IN BRCA_NNP 1_CD in_IN the_DT BG-_NNP 1_CD human_JJ ovarian_NN
          adenocarcinoma_NN cells_NNS ._. BG-_NNP 1_CD human_JJ ovarian_NN adenocarcinoma_NN
          cells_NNS were_VBD infected_VBN with_IN a_DT retroviral_NN construct_VB composed_VBN
          of_IN an_DT antisense_NN 900_CD base-pair_JJ cDNA_NN sequence_NN of_IN the_DT
          amino-terminal_JJ region_NN of_IN 
          BRCA_NNP 1_CD ._. Three_CD experiments_NNS (_( two_CD of_IN
          which_WDT were_VBD from_IN independently_RB made_VBN supernatants_NNS )_) showed_VBD
          that_DT infection_NN of_IN pLXSN_NN (_( vector_NN alone_RB )_) and_CC 
          BRCA_NNP 1_CD antisense_NN retroviral_NN
          constructs_NNS into_IN BG-_NNP 1_CD cells_NNS yielded_VBD G_NNP 418_CD -_: resistant_JJ
          colonies_NNS at_IN similar_JJ rates_NNS (_( titers_NNS ranged_VBD from_IN 0_CD ._. 78_CD to_TO 4_CD ._. 2_CD
          ×_NN 10_CD 4_CD colony-forming_JJ units_NNS /_NN ml_NN )_) ._. The_DT same_JJ vectors_NNS were_VBD
          also_RB directly_RB transfected_JJ into_IN BG-_NNP 1_CD cells_NNS at_IN an_DT
          efficiency_NN of_IN 6_CD ._. 3_CD ×_NN 10_CD -_: 5_CD for_IN the_DT anti-sense_JJ 
          BRCA_NNP 1_CD or_CC 9_CD ._. 9_CD ×_NN 10_CD -_: 5_CD for_IN the_DT control_NN
          plasmid_NN (_( pLXSN_NN )_) ._. Neomycin-resistant_NNP colonies_NNS were_VBD pooled_VBN
          and_CC examined_VBN for_IN 
          BRCA_NNP 1_CD message_NN levels_NNS by_IN
          ribonuclease_NN protection_NN assay_NN ._. 
          BRCA_NNP 1_CD antisense_NN infected_JJ cells_NNS
          contained_VBD significantly_RB less_JJR 
          BRCA_NNP 1_CD message_NN than_IN control_NN LXSN_NNP
          infected_JJ cells_NNS ,_, whether_IN cultured_JJ in_IN the_DT presence_NN or_CC
          absence_NN of_IN estrogen_NN (_( Fig_NNP ._. 1_LS a_DT )_) ._. Although_IN there_EX appears_VBZ to_TO
          be_VB no_DT detectable_JJ amounts_NNS of_IN BRCA_NNP 1_CD RNA_NNP present_JJ after_IN
          estrogen_NN withdrawal_NN ,_, low_JJ levels_NNS of_IN protein_NN can_MD be_VB
          detected_VBN by_IN western_JJ blot_NN analysis_NN [_NN 10_CD ]_NN ._.
          Subclones_NNP were_VBD also_RB isolated_VBN from_IN BRCA_NNP 1_CD antisense_NN
          infected_JJ cells_NNS ,_, or_CC LXSN_NNP infected_JJ cells_NNS (_( NEO_NNP )_) ._. Western_JJ
          blot_NN analysis_NN demonstrated_VBN that_IN all_DT of_IN the_DT antisense_NN
          BRCA_NNP 1_CD clones_NNS had_VBD reduced_VBN levels_NNS of_IN BRCA_NNP 1_CD protein_NN compared_VBN
          with_IN the_DT NEO_NNP clones_NNS ,_, and_CC one_CD antisense_NN clone_NN (_( AS-_NNP 4_LS )_) had_VBD
          very_RB low_JJ levels_NNS of_IN BRCA_NNP 1_CD protein_NN ,_, although_IN it_PRP was_VBD not_RB
          totally_RB absent_JJ (_( Fig_NNP ._. 1_LS b_SYM )_) ._.
        
        
          Effects_NNPS of_IN reduced_VBN BRCA_NNP 1_CD expression_NN on_IN in_IN
          vitrogrowth_NN
          Pooled_NNP populations_NNS of_IN antisense_NN 
          BRCA_NNP 1_CD BG-_NNP 1_CD colonies_NNS were_VBD examined_VBN
          for_IN growth_NN in_IN the_DT absence_NN or_CC presence_NN of_IN supplemented_JJ
          estrogen_NN ._. Three_CD independently_RB infected_JJ cultures_NNS of_IN 
          BRCA_NNP 1_CD antisense_NN cells_NNS demonstrated_VBD
          a_DT resistance_NN to_TO cell_NN death_NN induced_VBN by_IN withdrawal_NN from_IN
          estrogen_NN over_IN a_DT 6_CD -_: day_NN period_NN ,_, as_RB well_RB as_IN a_DT threefold_RB to_TO
          sixfold_RB increase_VB in_IN cell_NN growth_NN compared_VBN with_IN control_NN
          cells_NNS in_IN the_DT presence_NN of_IN estrogen_NN treatment_NN (_( Fig_NNP ._. 3_LS )_) ._. In_IN
          order_NN to_TO investigate_VB further_RB whether_IN reduction_NN of_IN BRCA_NNP 1_CD
          protein_NN had_VBD an_DT effect_NN on_IN hormone-dependent_JJ cell_NN growth_NN ,_,
          BG-_NNP 1_CD antisense_NN and_CC control_NN cells_NNS were_VBD grown_VBN in_IN
          estrogen-deprived_JJ conditions_NNS for_IN an_DT extended_VBN period_NN of_IN
          time_NN ._. During_IN the_DT first_JJ 5_CD days_NNS ,_, both_DT groups_NNS continued_VBD to_TO
          proliferate_VBP in_IN the_DT absence_NN of_IN estrogen_NN ,_, but_CC the_DT BRCA_NNP 1_CD
          antisense_NN group_NN continued_VBD to_TO grow_VB for_IN the_DT next_JJ 10_CD days_NNS ,_,
          whereas_IN control_NN cells_NNS decreased_VBD in_IN number_NN (_( Fig_NNP ._. 2_LS a_DT )_) ._.
          In_IN order_NN to_TO avoid_VB the_DT problem_NN of_IN a_DT mixed_JJ population_NN of_IN
          cells_NNS expressing_VBG various_JJ levels_NNS of_IN BRCA_NNP 1_CD ,_, subclones_NNS were_VBD
          isolated_VBN from_IN infected_JJ populations_NNS of_IN 
          BRCA_NNP 1_CD antisense_NN infected_JJ BG-_NNP 1_CD cells_NNS
          and_CC control_NN LXSN_NNP infected_JJ BG-_NNP 1_CD cells_NNS (_( NEO_NNP )_) ._. Figure_NN
          2_CD bshows_NNS BG-_NNP 1_CD parental_JJ and_CC NEO_NNP clones_NNS exhibited_VBN up_RP to_TO a_DT
          37_CD %_NN decrease_NN in_IN cell_NN number_NN during_IN a_DT 3_CD -_: day_NN period_NN of_IN
          estrogen_NN withdrawal_NN ,_, whereas_IN antisense_NN 
          BRCA_NNP 1_CD clones_NNS showed_VBD as_RB much_RB as_IN a_DT
          twofold_NN increase_NN in_IN cell_NN number_NN during_IN the_DT same_JJ time_NN
          period_NN ._. In_IN an_DT attempt_NN to_TO determine_VB if_IN increased_VBN survival_NN
          of_IN the_DT antisense_NN cells_NNS was_VBD do_VBP to_TO increased_VBN proliferation_NN
          of_IN the_DT antisense_NN cells_NNS or_CC decreased_VBD death_NN rate_NN ,_, the_DT
          number_NN of_IN trypan_NN blue_JJ positive_JJ ,_, non-viable_JJ were_VBD examined_VBN
          after_IN 14_CD days_NNS without_IN estrogen_NN ._. There_EX were_VBD 5_CD -_: 10_CD -_: fold_VB more_RBR
          dead_JJ cells_NNS present_JJ in_IN the_DT media_NNS of_IN control_NN cells_NNS (_( BG-_NNP 1_CD
          parental_JJ and_CC NEO_NNP clone_NN )_) then_RB in_IN the_DT 
          BRCA_NNP 1_CD antisense_NN clone_NN AS-_NNP 4_CD (_( data_NNS
          not_RB shown_VBN )_) ._. It_PRP appeared_VBD that_DT resistance_NN to_TO cell_NN death_NN
          plays_VBZ a_DT significant_JJ role_NN in_IN the_DT survival_NN of_IN 
          BRCA_NNP 1_CD antisense_NN cells_NNS to_TO estrogen_NN
          withdrawal_NN ._. Figure_NN 2_CD bagain_NN demonstrates_VBZ the_DT ability_NN of_IN
          the_DT BRCA_NNP 1_CD antisense_NN sub-clones_JJ to_TO survive_VB estrogen_NN
          deprivation_NN ._. In_IN the_DT presence_NN of_IN estrogen_NN ,_, three_CD out_IN of_IN
          the_DT four_CD antisense_NN 
          BRCA_NNP 1_CD clones_NNS exhibited_VBN a_DT growth_NN
          advantage_NN over_IN NEO_NNP clones_NNS or_CC the_DT BG-_NNP 1_CD parental_JJ population_NN
          (_( Fig_NNP ._. 2_LS b_SYM )_) ._. Antisense_NNP 
          BRCA_NNP 1_CD clones_NNS 1_CD ,_, 3_CD and_CC 4_CD showed_VBD a_DT
          10_CD -_: fold_VB to_TO 16_CD -_: fold_VB increase_NN in_IN cell_NN number_NN between_IN days_NNS 5_CD
          and_CC 8_CD after_IN estrogen_NN treatment_NN compared_VBN with_IN only_RB a_DT
          threefold_RB to_TO fivefold_JJ increase_NN of_IN cell_NN number_NN in_IN NEO_NNP
          clones_NNS and_CC BG-_NNP 1_CD parental_JJ cells_NNS (_( Fig_NNP ._. 2_LS b_SYM )_) ._. The_DT AS-_NNP 4_CD clone_NN ,_,
          which_WDT had_VBD the_DT lowest_JJS levels_NNS of_IN BRCA_NNP 1_CD protein_NN ,_, showed_VBD a_DT
          highly_RB significant_JJ (_( 16_CD -_: fold_VB ;_: 
          P_NN <_NN 0_CD ._. 01_CD )_) stimulation_NN of_IN growth_NN
          between_IN days_NNS 5_CD and_CC 8_CD of_IN estrogen_NN induction_NN (_( Figs_NNP 2_CD band_NN
          4_LS )_) ._. In_IN summary_NN ,_, although_IN three_CD out_IN of_IN four_CD of_IN the_DT
          antisense_NN 
          BRCA_NNP 1_CD clones_NNS had_VBD a_DT growth_NN advantage_NN
          in_IN the_DT presence_NN of_IN estrogen_NN ,_, all_DT four_CD antisense_NN 
          BRCA_NNP 1_CD clones_NNS showed_VBD enhanced_JJ
          survival_NN in_IN estrogen-depleted_JJ media_NNS ._.
        
        
          Anchorage_NNP independent_JJ growth_NN of_IN BG-_NNP 1_CD clones_NNS
          Anchorage_NNP independent_JJ growth_NN is_VBZ a_DT common_JJ property_NN of_IN
          many_JJ transformed_VBN cells_NNS ._. Therefore_RB ,_, the_DT 
          BRCA_NNP 1_CD antisense_NN subclones_NNS were_VBD also_RB
          studied_VBN for_IN anchorage_NN independent_JJ growth_NN in_IN a_DT semisoft_NN
          agar_NN medium_NN with_IN and_CC without_IN supplemented_JJ estrogen_NN ._.
          Table_NNP 1_CD shows_VBZ that_DT colony_NN formation_NN efficiencies_NNS on_IN
          plastic_NN of_IN control_NN (_( NEO_NNP )_) and_CC 
          BRCA_NNP 1_CD anti-sense_JJ (_( AS-_NNP 4_LS )_) cells_NNS were_VBD
          similar_JJ in_IN estrogen-depleted_JJ and_CC estrogen-containing_JJ
          media_NNS ._. However_RB ,_, the_DT BG-_NNP 1_CD control_NN clone_NN (_( NEO_NNP )_) was_VBD unable_JJ
          to_TO form_VB colonies_NNS (_( fewer_JJR than_IN one_CD colony_NN per_IN 10_CD 4_CD cells_NNS
          plated_JJ )_) in_IN agar_NN without_IN the_DT addition_NN of_IN estrogen_NN ,_, whereas_IN
          the_DT BG-_NNP 1_CD antisense_NN 
          BRCA_NNP 1_CD clone_NN was_VBD able_JJ to_TO form_VB soft_JJ
          agar_NN colonies_NNS in_IN estrogen_NN depleted_VBD conditions_NNS (_( 10_CD ±_NN 2_CD ._. 9_CD
          colonies_NNS per_IN 10_CD 4_CD cells_NNS plated_JJ )_) ._. In_IN the_DT presence_NN of_IN
          estrogen_NN ,_, both_DT NEO_NNP and_CC AS-_NNP 4_CD were_VBD able_JJ to_TO form_VB colonies_NNS ;_:
          however_RB ,_, there_EX was_VBD a_DT significant_JJ difference_NN (_( 
          P_NN <_NN 0_CD ._. 01_CD )_) in_IN the_DT ability_NN to_TO form_VB
          colonies_NNS in_IN agar_NN between_IN AS-_NNP 4_CD (_( 133_CD colonies_NNS )_) and_CC the_DT
          control_NN clone_NN (_( six_CD colonies_NNS )_) ._. These_DT data_NNS suggest_VBP a_DT
          correlation_NN between_IN the_DT loss_NN of_IN BRCA_NNP 1_CD protein_NN and_CC an_DT
          increased_VBN survival_NN /_NN growth_NN advantage_NN in_IN
          anchorage-independent_JJ conditions_NNS ._.
        
        
          Effects_NNPS of_IN reduced_VBN BRCA_NNP 1_CD protein_NN on_IN in_IN vivo_NN tumor_NN
          cell_NN growth_NN
          Because_IN the_DT AS-_NNP 4_CD clone_NN showed_VBD a_DT growth_NN advantage_NN in_IN
          soft_JJ agar_NN ,_, a_DT phenotype_NN that_WDT may_MD be_VB correlated_JJ with_IN the_DT
          ability_NN to_TO form_VB tumors_NNS 
          in_IN vivo_NN ,_, the_DT BRCA_NNP 1_CD antisense_NN
          sub-clone_JJ AS-_NNP 4_CD was_VBD evaluated_VBN for_IN its_PRP$ ability_NN to_TO form_VB
          subcutaneous_JJ tumors_NNS in_IN ovariectomized_JJ athymic_JJ mice_NNS in_IN the_DT
          presence_NN or_CC absence_NN of_IN an_DT estrogen_NN pellet_NN ._. Mice_NNS were_VBD
          injected_VBN subcutaneously_RB with_IN AS-_NNP 4_CD cells_NNS in_IN matrigel_NN on_IN
          one_CD side_NN of_IN each_DT mouse_NN and_CC NEO_NNP cells_NNS in_IN matrigel_NN on_IN the_DT
          other_JJ side_NN ._. Of_IN the_DT mice_NNS injected_VBN ,_, 50_CD %_NN received_VBD an_DT
          implanted_VBN estrogen_NN pellet_NN (_( 0_CD ._. 18_CD mg_NN estrogen_NN )_) that_WDT was_VBD
          designed_VBN to_TO release_VB estrogen_NN for_IN 60_CD days_NNS ._. In_IN the_DT absence_NN
          of_IN estrogen_NN ,_, a_DT significant_JJ difference_NN was_VBD detected_VBN in_IN
          tumorigenic_JJ growth_NN between_IN AS-_NNP 4_CD and_CC NEO_NNP cells_NNS (_( Fig_NNP ._. 5_LS b_SYM )_) ._.
          Almost_RB twice_RB as_IN many_JJ sites_NNS were_VBD tumor_NN positive_JJ for_IN the_DT
          AS-_NNP 4_CD clones_NNS than_IN for_IN NEO_NNP injected_VBD sites_NNS ._. 100_CD %_NN (_( 14_CD /_NN 14_CD )_)
          Tumor_NNP formation_NN was_VBD reached_VBN for_IN all_DT AS-_NNP 4_CD clones_NNS 42_CD days_NNS
          after_IN injection_NN ,_, compared_VBN with_IN 57_CD %_NN (_( eight_CD out_IN of_IN 14_CD )_)
          positive_JJ tumor_NN formation_NN of_IN the_DT NEO_NNP sites_NNS (_( Fig_NNP ._. 5_LS b_SYM ,_, upper_JJ
          panel_NN )_) ._. AS-_NNP 4_CD cells_NNS also_RB formed_VBN tumors_NNS that_WDT averaged_VBD twice_RB
          the_DT size_NN of_IN NEO_NNP control_NN tumors_NNS (_( Fig_NNP ._. 5_LS b_SYM ,_, lower_JJR
          panel_NN )_) ._.
          BG-_NNP 1_CD cells_NNS without_IN matrigel_NN were_VBD nontumorigenic_JJ in_IN
          athymic_JJ male_JJ or_CC female_JJ mice_NNS (_( 0_CD positive_JJ sites_NNS /_NN 20_CD sites_NNS
          injected_VBN at_IN 5_CD ×_NN 10_CD 6_CD cells_NNS per_IN site_NN )_) ,_, but_CC these_DT cells_NNS formed_VBD
          large_JJ ,_, progressively_RB growing_VBG tumors_NNS when_WRB injected_VBN with_IN
          matrigel_NN in_IN the_DT presence_NN of_IN estrogen_NN (_( Fig_NNP ._. 5_LS a_DT )_) ._. These_DT
          tumors_NNS were_VBD very_RB large_JJ (_( >_NN 1_CD cm_NN diameter_NN )_) and_CC did_VBD not_RB
          regress_NNS even_RB though_IN the_DT estrogen_NN pellet_NN was_VBD effective_JJ for_IN
          only_RB 60_CD days_NNS (_( Fig_NNP ._. 5_LS a_DT ,_, lower_JJR panel_NN )_) ._. Similar_JJ to_TO the_DT agar_NN
          experiments_NNS ,_, both_DT the_DT BRCA_NNP 1_CD antisense_NN clone_NN and_CC LXSN_NNP
          control_NN clone_NN were_VBD positive_JJ for_IN tumor_NN formation_NN in_IN the_DT
          presence_NN of_IN estrogen_NN ._. AS-_NNP 4_CD cells_NNS formed_VBD tumors_NNS with_IN half_NN
          of_IN the_DT latency_NN of_IN control_NN cells_NNS in_IN the_DT presence_NN of_IN
          implanted_VBN estrogen_NN (_( Fig_NNP ._. 5_LS a_DT ,_, upper_JJ panel_NN ;_: 11_CD days_NNS versus_CC
          21_CD days_NNS until_IN tumor_NN formation_NN )_) ._. Neither_DT AS-_NNP 4_CD nor_CC NEO_NNP
          cells_NNS formed_VBN progressively_RB growing_VBG tumors_NNS in_IN the_DT absence_NN
          of_IN estrogen_NN ,_, however_RB ._. All_DT tumors_NNS in_IN the_DT mice_NNS without_IN
          estrogen_NN pellets_NNS had_VBD started_VBN to_TO regress_NNS by_IN 71_CD days_NNS after_IN
          injection_NN ._. The_DT observed_VBN tumor_NN regression_NN was_VBD not_RB
          surprising_JJ ,_, because_IN matrigel_NN is_VBZ not_RB stable_JJ for_IN longer_JJR
          than_IN 14_CD days_NNS in_IN culture_NN ,_, and_CC probably_RB not_RB 
          in_IN vivo_NN either_DT (_( personal_JJ
          communication_NN ;_: Collaborative_NNP Biomedical_NNP Products_NNPS ,_,
          Bedford_NNP ,_, MA_NNP ,_, USA_NNP )_) ._. By_IN day_NN 71_CD ,_, the_DT matrigel_NN would_MD no_RB
          longer_RB confer_VB an_DT optimal_NN growth_NN environment_NN for_IN BG-_NNP 1_CD
          cells_NNS ._.
        
        
          Discussion_NNP
          The_DT present_JJ studies_NNS show_VBP that_DT reduction_NN of_IN BRCA_NNP 1_CD
          levels_NNS ,_, using_VBG an_DT antisense_NN retroviral_NN vector_NN in_IN the_DT
          estrogen_NN dependent_JJ BG-_NNP 1_CD ovarian_NN carcinoma_NN cell_NN line_NN ,_, may_MD
          aid_VB in_IN confirmation_NN of_IN the_DT hypothesis_NNS that_IN 
          BRCA_NNP 1_CD functions_NNS as_IN a_DT tumor_NN
          suppressor_NN gene_NN by_IN playing_VBG a_DT pivotal_JJ role_NN in_IN the_DT balance_NN
          between_IN cell_NN death_NN and_CC cell_NN proliferation_NN ._. 
          BRCA_NNP 1_CD RNA_NNP and_CC protein_NN levels_NNS were_VBD
          successfully_RB reduced_VBN in_IN pooled_VBN and_CC isolated_VBN subclones_NNS of_IN
          antisense-infected_JJ populations_NNS of_IN BG-_NNP 1_CD cells_NNS ._. Decreased_NNP 
          BRCA_NNP 1_CD levels_NNS appeared_VBD to_TO affect_VB the_DT
          ability_NN of_IN BG-_NNP 1_CD cells_NNS to_TO arrest_VB growth_NN or_CC die_VB in_IN the_DT
          absence_NN of_IN estrogenic_JJ growth-inducing_JJ conditions_NNS ._. We_PRP
          found_VBD that_IN 
          BRCA_NNP 1_CD antisense_NN cells_NNS ,_, both_DT as_IN
          pooled_VBN populations_NNS and_CC individual_JJ subclones_NNS ,_, also_RB
          exhibited_VBN enhanced_JJ growth_NN in_IN monolayer_NN culture_NN on_IN plastic_NN
          in_IN the_DT presence_NN of_IN estrogen_NN compared_VBN with_IN control_NN
          vector-infected_JJ colonies_NNS ._. All_DT BRCA_NNP 1_CD antisense_NN subclones_NNS
          were_VBD able_JJ to_TO proliferate_VBP as_RB well_RB as_IN exhibit_NN a_DT decreased_VBN
          death_NN rate_NN in_IN estrogen-deprived_JJ media_NNS ,_, whereas_IN parental_JJ
          and_CC control_NN subclones_NNS failed_VBD to_TO grow_VB ._. Death_NN after_IN
          estrogen_NN withdrawal_NN has_VBZ been_VBN shown_VBN in_IN previous_JJ studies_NNS
          using_VBG BG-_NNP 1_CD cells_NNS [_NN 13_CD ,_, 35_CD ]_NN ._. BRCA_NNP 1_CD antisense_NN subclones_NNS
          demonstrated_VBD other_JJ traits_NNS associated_VBN with_IN a_DT tumorigenic_JJ
          phenotype_NN ,_, such_JJ as_IN the_DT ability_NN to_TO grow_VB in_IN soft_JJ agar_NN
          independent_JJ of_IN estrogen_NN ,_, whereas_IN control_NN clones_NNS could_MD
          only_RB form_VB colonies_NNS with_IN the_DT addition_NN of_IN estrogen_NN ._. In_IN
          ovariectomized_JJ nude_JJ mice_NNS ,_, a_DT BRCA_NNP 1_CD antisense_NN clone_NN (_( AS-_NNP 4_LS )_)
          was_VBD examined_VBN for_IN tumorigenicity_NN compared_VBN with_IN a_DT control_NN
          clone_NN (_( NEO_NNP )_) ._. The_DT AS-_NNP 4_CD clone_NN formed_VBD a_DT greater_JJR number_NN of_IN
          and_CC larger_JJR tumors_NNS than_IN NEO_NNP in_IN the_DT absence_NN of_IN estrogen_NN ,_,
          and_CC in_IN general_JJ formed_VBN tumors_NNS faster_RBR in_IN the_DT presence_NN of_IN
          estrogen_NN ._. The_DT main_JJ conclusion_NN from_IN these_DT studies_NNS is_VBZ that_IN
          BG-_NNP 1_CD clones_NNS with_IN reduced_VBN levels_NNS of_IN BRCA_NNP 1_CD protein_NN have_VBP a_DT
          survival_NN advantage_NN over_IN controls_NNS in_IN the_DT absence_NN of_IN
          estrogen_NN both_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN ._. 
          The_DT response_NN of_IN 
          BRCA_NNP 1_CD mRNA_NN and_CC protein_NN levels_NNS to_TO
          mitogens_NNS and_CC hormones_NNS 
          in_IN vitro_NN suggests_VBZ that_IN 
          BRCA_NNP 1_CD may_MD play_VB a_DT role_NN in_IN regulation_NN
          of_IN cell_NN growth_NN or_CC maintenance_NN [_NN 21_CD ]_NN ._. During_IN estrous_JJ ,_, many_JJ
          hormones_NNS and_CC growth_NN factors_NNS interact_NN in_IN a_DT complex_JJ manner_NN
          as_IN survival_NN factors_NNS and_CC inducers_NNS of_IN cell_NN proliferation_NN ,_,
          which_WDT are_VBP then_RB balanced_VBN with_IN growth_NN inhibitors_NNS [_NN 36_CD ,_, 37_CD ,_,
          38_CD ,_, 39_CD ,_, 40_CD ]_NN ._. The_DT mechanism_NN by_IN which_WDT 
          BRCA_NNP 1_CD can_MD regulate_VB or_CC influence_VB
          these_DT processes_VBZ has_VBZ not_RB yet_RB been_VBN identified_VBN ._. It_PRP has_VBZ been_VBN
          shown_VBN that_IN 
          BRCA_NNP 1_CD is_VBZ induced_VBN as_IN a_DT result_NN of_IN the_DT
          mitogenic_JJ activity_NN of_IN the_DT estrogen_NN receptor_NN in_IN estrogen_NN
          receptor-positive_JJ cells_NNS [_NN 9_CD ,_, 10_CD ]_NN ._. Direct_JJ estrogen_NN
          stimulation_NN is_VBZ not_RB required_VBN for_IN 
          BRCA_NNP 1_CD transcription_NN ,_, however_RB [_NN 9_CD ,_,
          41_CD ]_NN ._. In_IN support_NN of_IN this_DT ,_, 
          BRCA_NNP 1_CD expression_NN has_VBZ been_VBN shown_VBN to_TO
          occur_VB in_IN the_DT mouse_NN ovary_JJ (_( granulosa_NN and_CC thecal_NN cells_NNS of_IN
          small_JJ and_CC medium_NN follicles_NNS )_) independent_JJ of_IN hormonal_NN
          status_NN ,_, and_CC even_RB in_IN ovaries_NNS from_IN estrogen_NN receptor_NN -_: /_NN -_:
          deficient_NN mice_NNS [_NN 41_CD ,_, 42_CD ]_NN ._. In_IN contrast_NN ,_, the_DT tumors_NNS from_IN
          patients_NNS with_IN 
          BRCA_NNP 1_CD mutations_NNS appear_VBP to_TO have_VB
          downregulation_NN of_IN estrogen_NN receptors_NNS [_NN 43_CD ,_, 44_CD ,_, 45_CD ]_NN ._.
          Previous_JJ experiments_NNS in_IN our_PRP$ laboratory_NN showed_VBD that_IN
          another_DT hormone_NN ,_, progesterone_NN ,_, could_MD also_RB cause_VB a_DT modest_JJ
          increase_NN of_IN 
          BRCA_NNP 1_CD mRNA_NN in_IN BG-_NNP 1_CD cells_NNS after_IN 24_CD h_NN
          exposure_NN without_IN an_DT increase_NN in_IN growth_NN (_( unpublished_JJ
          data_NNS )_) ._. Progesterone_NNP has_VBZ been_VBN found_VBN [_NN 46_CD ]_NN to_TO inhibit_VB cell_NN
          proliferation_NN and_CC induce_VB apoptosis_NNS significantly_RB in_IN two_CD
          ovarian_NN carcinoma_NN cell_NN lines_NNS ._. Thus_RB ,_, although_IN 
          BRCA_NNP 1_CD may_MD not_RB be_VB regulated_VBN directly_RB
          by_IN hormones_NNS ,_, the_DT BRCA_NNP 1_CD gene_NN product_NN may_MD be_VB involved_VBN in_IN
          the_DT regulation_NN of_IN hormone_NN response_NN pathways_NNS ,_, and_CC the_DT
          present_JJ results_NNS may_MD demonstrate_VB that_DT loss_NN of_IN BRCA_NNP 1_CD may_MD
          result_VB in_IN loss_NN of_IN inhibitory_NN control_NN of_IN these_DT mitogenic_JJ
          pathways_NNS ._.
          
          BRCA_NNP 1_CD transcription_NN is_VBZ regulated_VBN
          with_IN the_DT cell_NN cycle_NN ,_, and_CC highest_JJS levels_NNS correlate_VBP with_IN
          the_DT G_NNP 1_CD /_NN S-_NNP phase_NN boundary_NN [_NN 5_CD ,_, 9_CD ,_, 41_CD ,_, 47_CD ,_, 48_CD ,_, 49_CD ]_NN ._. The_DT
          present_JJ studies_NNS show_VBP that_DT reduction_NN of_IN 
          BRCA_NNP 1_CD mRNA_NN and_CC protein_NN can_MD result_VB
          in_IN increased_VBN proliferation_NN of_IN BG-_NNP 1_CD ovarian_NN cancer_NN cells_NNS 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN ,_, suggesting_VBG that_IN 
          BRCA_NNP 1_CD may_MD normally_RB be_VB acting_VBG as_IN a_DT
          growth_NN inhibitor_NN ._. Similar_JJ to_TO our_PRP$ findings_NNS with_IN ovarian_NN
          carcinoma_NN cells_NNS ,_, accelerated_VBD growth_NN ,_, anchorage_NN
          independence_NN and_CC tumorigenicity_NN is_VBZ associated_VBN with_IN 
          BRCA_NNP 1_CD antisense_NN introduction_NN into_IN
          mouse_NN NIH_NNP 3_CD T_NN 3_CD cells_NNS [_NN 50_CD ]_NN ._. In_IN addition_NN ,_, increased_VBN
          proliferation_NN of_IN mammary_JJ cells_NNS is_VBZ induced_VBN with_IN antisense_NN
          oligonucleotides_NNS to_TO 
          BRCA_NNP 1_CD [_NN 51_CD ]_NN ._. Conversely_RB ,_,
          introduction_NN of_IN full-length_JJ 
          BRCA_NNP 1_CD by_IN retrovirus-mediated_JJ gene_NN
          transfer_NN inhibited_VBD growth_NN of_IN breast_NN and_CC ovarian_NN cancer_NN
          cell_NN lines_NNS in_IN both_DT 
          in_IN vitro_NN and_CC 
          in_IN vivo_NN experiments_NNS [_NN 51_CD ]_NN ,_, and_CC
          transfection_NN of_IN 
          BRCA_NNP 1_CD into_IN colon_NN cancer_NN cells_NNS
          inhibited_VBD new_JJ DNA_NNP synthesis_NN by_IN 50_CD %_NN in_IN addition_NN to_TO
          inhibition_NN of_IN S-_NNP phase_NN progression_NN ,_, possibly_RB through_IN
          direct_JJ transactivation_NN of_IN the_DT cell_NN cycle_NN inhibitor_NN 
          p_NN 21_CD WAF_NNP 1_CD /_NN CIP_NNP 1_CD [_NN 49_CD ]_NN ._.
          In_IN multicellular_NN mammalian_JJ organisms_NNS ,_, a_DT balance_NN
          between_IN cell_NN proliferation_NN and_CC cell_NN death_NN is_VBZ extremely_RB
          important_JJ for_IN the_DT maintenance_NN of_IN normal_JJ healthy_JJ tissues_NNS ._.
          This_DT is_VBZ especially_RB important_JJ during_IN early_JJ embryonic_JJ
          development_NN as_RB well_RB as_IN in_IN the_DT development_NN and_CC function_NN of_IN
          adult_NN tissues_NNS such_JJ as_IN the_DT gonadal_NN cells_NNS (_( ie_NN ovarian_NN and_CC
          testes_NNS )_) [_NN 41_CD ,_, 48_CD ]_NN ._. For_IN example_NN ,_, 
          BRCA_NNP 1_CD expression_NN is_VBZ critical_JJ during_IN
          development_NN ,_, as_IN evidenced_VBN by_IN the_DT embryonic_JJ lethality_NN in_IN
          transgenic_JJ knockout_NN mice_NNS [_NN 29_CD ,_, 30_CD ,_, 52_CD ]_NN ._. Alternatively_RB ,_,
          overexpression_NN of_IN 
          BRCA_NNP 1_CD may_MD activate_VBP apoptosis_NNS or_CC
          cell_NN death_NN [_NN 14_CD ]_NN ._. Human_JJ prostate_NN cells_NNS with_IN an_DT introduced_VBN
          wild-type_JJ 
          BRCA_NNP 1_CD cDNA_NN demonstrated_VBD a_DT threefold_RB
          to_TO sixfold_RB increase_VB in_IN chemosensitivity_NN ,_, as_RB well_RB as_IN an_DT
          increased_VBN susceptibility_NN to_TO drug-induced_JJ apoptosis_NNS [_NN 53_CD ]_NN ._.
          We_PRP found_VBD that_IN clones_NNS with_IN even_RB moderately_RB reduced_VBN levels_NNS
          of_IN 
          BRCA_NNP 1_CD protein_NN appeared_VBD to_TO be_VB
          relatively_RB resistant_JJ to_TO death_NN due_JJ to_TO estrogen_NN
          deprivation_NN ._. Previous_JJ studies_NNS in_IN our_PRP$ laboratory_NN showed_VBD
          that_DT response_NN of_IN parental_JJ BG-_NNP 1_CD cells_NNS and_CC antisense_NN clones_NNS
          to_TO gamma_NN radiation_NN were_VBD consistent_JJ with_IN a_DT 
          p_NN 53_CD wildtype_NN phenotype_NN ,_, indicating_VBG
          that_DT loss_NN of_IN estrogen_NN dependence_NN is_VBZ probably_RB not_RB due_JJ to_TO a_DT
          
          p_NN 53_CD mutation_NN (_( unpublished_JJ data_NNS )_) ._.
          Shao_NNP 
          et_CC al_NN [_NN 14_CD ]_NN demonstrated_VBN that_IN 
          BRCA_NNP 1_CD transfected_JJ into_IN mouse_NN 3_CD T_NN 3_CD
          fibroblasts_NNS resulted_VBD in_IN increased_VBN programmed_VBN cell_NN death_NN ._.
          In_IN support_NN of_IN this_DT hypothesis_NNS ,_, it_PRP has_VBZ been_VBN shown_VBN that_DT 
          p_NN 53_CD and_CC 
          BRCA_NNP 1_CD can_MD form_VB stable_JJ complexes_NNS ,_,
          and_CC can_MD coactivate_NN 
          p_NN 21_CD and_CC 
          bax_NN genes_NNS ,_, which_WDT may_MD lead_VB to_TO the_DT
          activation_NN of_IN the_DT apoptosis_NNS pathway_NN [_NN 15_CD ]_NN ._. The_DT present_JJ
          data_NN ,_, which_WDT show_VBP that_IN cells_NNS with_IN a_DT reduction_NN in_IN BRCA_NNP 1_CD
          have_VBP a_DT survival_NN advantage_NN in_IN conditions_NNS where_WRB control_NN
          cells_NNS fail_VBP to_TO thrive_VB ,_, also_RB supports_VBZ this_DT hypothesis_NNS ._.
          Like_IN 
          p_NN 53_CD ,_, 
          BRCA_NNP 1_CD has_VBZ also_RB been_VBN implicated_VBN in_IN
          DNA_NNP damage_NN and_CC repair_NN pathways_NNS [_NN 7_CD ,_, 48_CD ,_, 54_CD ]_NN ._. According_VBG to_TO
          this_DT model_NN ,_, cells_NNS without_IN normal_JJ 
          BRCA_NNP 1_CD activity_NN may_MD accumulate_VBP
          genetic_JJ alterations_NNS as_IN a_DT result_NN of_IN failure_NN to_TO arrest_VB and_CC
          repair_NN DNA_NNP damage_NN or_CC self-destruct_JJ ,_, thereby_RB leading_VBG to_TO
          genomic_JJ instability_NN and_CC neoplastic_JJ progression_NN ._. It_PRP may_MD
          not_RB be_VB coincidental_JJ that_IN 
          BRCA_NNP 1_CD -_: mutant_JJ breast_NN cancers_NNS are_VBP
          preferentially_RB linked_VBN to_TO a_DT '_POS specific_JJ '_POS histopathologic_JJ
          pattern_NN that_WDT includes_VBZ a_DT high_JJ S-_NNP phase_NN fraction_NN of_IN cells_NNS ,_,
          aneuploidy_NN ,_, and_CC hormone_NN receptor-negative_JJ status_NN [_NN 45_CD ]_NN ._.
          In_IN addition_NN ,_, it_PRP has_VBZ been_VBN demonstrated_VBN [_NN 20_CD ]_NN that_IN
          hormone-dependent_JJ tumors_NNS such_JJ as_IN breast_NN and_CC ovarian_NN
          cancers_NNS have_VBP a_DT decreased_VBN ability_NN to_TO undergo_VB apoptosis_NNS ._.
          Although_IN mutations_NNS in_IN this_DT gene_NN are_VBP uncommon_JJ in_IN sporadic_JJ
          breast_NN and_CC ovarian_NN tumors_NNS ,_, 
          BRCA_NNP 1_CD expression_NN levels_NNS and_CC protein_NN
          levels_NNS have_VBP been_VBN found_VBN to_TO be_VB reduced_VBN in_IN sporadic_JJ human_JJ
          breast_NN carcinomas_NNS [_NN 16_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ]_NN ._. Other_JJ mechanisms_NNS
          that_WDT involve_VBP gene_NN regulation_NN may_MD allow_VB for_IN decreased_VBD
          expression_NN of_IN 
          BRCA_NNP 1_CD in_IN sporadic_JJ tumors_NNS ._.
          Hypermethylation_NNP has_VBZ been_VBN observed_VBN in_IN some_DT sporadic_JJ
          breast_NN tumors_NNS in_IN the_DT promoter_NN region_NN of_IN 
          BRCA_NNP 1_CD ,_, which_WDT may_MD account_VB for_IN
          decreased_VBD 
          BRCA_NNP 1_CD transcription_NN [_NN 55_CD ]_NN ._. Low_NNP
          BRCA_NNP 1_CD levels_NNS found_VBD in_IN sporadic_JJ cancers_NNS may_MD play_VB an_DT
          important_JJ role_NN in_IN tumorigenesis_NNS ._. The_DT present_JJ data_NN suggest_VBP
          that_WDT diminished_VBD levels_NNS of_IN BRCA_NNP 1_CD not_RB only_RB accelerate_VB
          proliferation_NN in_IN the_DT BG-_NNP 1_CD ovarian_NN carcinoma_NN cell_NN line_NN ,_,
          but_CC appear_VB to_TO alter_VB tumorigenesis_NNS ._. The_DT exact_JJ mechanism_NN
          may_MD be_VB unknown_JJ ,_, but_CC decreased_VBD 
          BRCA_NNP 1_CD levels_NNS appear_VBP to_TO affect_VB the_DT
          ability_NN to_TO arrest_VB growth_NN or_CC die_VB in_IN the_DT absence_NN of_IN
          estrogenic_JJ growth-inducing_JJ conditions_NNS ._. We_PRP propose_VBP that_IN
          the_DT loss_NN or_CC reduction_NN of_IN 
          BRCA_NNP 1_CD may_MD predispose_VB a_DT cell_NN
          population_NN to_TO neoplastic_JJ transformation_NN by_IN altering_VBG the_DT
          balance_NN between_IN cell_NN death_NN and_CC proliferation_NN /_NN survival_NN ,_,
          rendering_VBG it_PRP more_RBR sensitive_JJ to_TO secondary_JJ genetic_JJ
          changes_NNS ._.
        
      
    
  
